Krone24m
Bechterew’s disease: warning signs are often overlooked
It often begins before the age of 40, usually in the 20s or 30s: severe pain occurs in the lower lumbar spine. It usually ...
Uncover the surprising symptoms of Spinal Stenosis before it's too late
Spinal stenosis, characterized by the narrowing of the spinal canal, compresses neural elements and predominantly affects the ...
Everyday Health5d
Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy (SMA) is a rare genetic disorder that causes muscle weakness and disability, typically in young ...
labiotech4d
Spinal cord injury: Are we getting closer to a treatment?
Explore innovative treatments for spinal cord injury in clinical trials, including Lineage's OPC1 and NervGen's NVG-291, ...
voxelmatters1d
FDA clears Vy Spine’s 3D printed LumiVy OsteoVy PEKK Lumbar IBF
FDA clears Vy Spine's 3D printed LumiVy OsteoVy PEKK Lumbar IBF - which combines OXPEKK material and the OsteoVy lattice ...
Scholar Rock’s stock soars more than 315% on positive trial of treatment for spinal muscular atrophy
Scholar Rock Holdings Corp.’s stock soared more than 230% early Monday, after the clinical-stage biotech said a late-stage ...
U Medical School to study genetic solutions to back pain
Research seeks to identify genetic triggers that can change a person’s susceptibility to back pain and resulting ...
Spinal cord organoids could unlock safer treatment for pregnant women with epilepsy
University of Queensland researchers have made a significant step towards enabling women with epilepsy safer access to a ...
Becker's Spine Review2d
5 spine, orthopedic biologic companies to know
Regenexx: Regenexx was founded by two physicians who were the first in the world to apply stem cells from bone marrow concentrate for orthopedic injuries. The company recently partnered with McAllen, ...
Becker's Spine Review2d
VySpine's 3D-printed lumbar spine implant FDA cleared: 3 notes
VySpine earned FDA clearance for its LumiVy OsteoVy PEKK lumbar interbody fusion device, according to an Oct. 9 news release.
Scholar Rock Holding's Spinal Muscular Atrophy Drug Apitegromab Meets Primary Study Endpoint
Scholar Rock Holding said that its treatment for spinal muscular atrophy met primary endpoint targets in a phase 3 clinical trial. The late-stage biopharmaceutical company said Monday that Apitegromab ...